Status | Study |
Completed |
Study Name: Effect Of Curcuma Xanthorrhiza and Vitamin D3 Supplementation in SLE Patients With Hypovitamin D Condition: SLE Date: 2017-05-13 Interventions: Dietary Supplement: "Cholecalciferol" and "C. Xanthorrhiza&qu |
Not yet recruiting |
Study Name: ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer Condition: Rectal Adenocarcinoma Date: 2016-01-25 Interventions: Drug: LY2157299 Small molecule |
Recruiting |
Study Name: SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer Condition: Stage IA Non-Small Cell Lung Carcinoma Stage IB Non-Small Cell Lung Carcinoma Date: 2015-10-16 Interventions: Biological: Fresolimumab Given |
Recruiting |
Study Name: Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer Condition: Prostate Cancer Date: 2015-05-20 Interventions: Drug: Enzalutamide 160mg of en |
Completed |
Study Name: Evaluation of the Signaling Path of Emiline1-TGFβ in the Myogenic Tone of Resistance Arteries in a Population of Normotensive and Hypertensive Subjects Condition: Hypertension Date: 2014-11-28 |
Active, not recruiting |
Study Name: TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC Condition: EBV-positive Nasopharyngeal Carcinoma Date: 2014-02-14 Interventions: Biological: DNR.NPC-specific T cells |
Recruiting |
Study Name: Study of Lymphodepletion Plus Adoptive Cell Transfer With TGF-beta Resistant (DNRII) and NGFR Transduced T-Cells Followed by High Dose Interleukin-2 in Participants With Metastatic Melanoma Condition: Melanoma Date: 2013-09-27 Interventions: Drug: Cyclophosphamide 60 mg/k |
Withdrawn |
Study Name: Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome Condition: Marfan Syndrome Date: 2011-05-25 Interventions: Other: Blood draw This study includes one blood draw to measure circulating blood levels of TGF-B. |
Terminated |
Study Name: Anti-TGF-beta Therapy in Patients With Myelofibrosis Condition: Myelofibrosis Primary Myelofibrosis Polycythemia Vera, Pos Date: 2011-02-07 Interventions: Biological: monoclonal antibody to TGF-beta starting dose of 1mg/kg intravenous over approximately 1 hou |
Completed |
Study Name: Fresolimumab In Systemic Sclerosis Condition: Diffuse Systemic Sclerosis Date: 2011-01-25 Interventions: Drug: Fresolimumab intravenous fresolimumab 1mg/kg, first 8 patients; 5 mg/kg following 8 patients |